Analyst Consensus ?
ConsensusBuy52 ratings
Bullish3771.2%
Neutral1528.8%
Bearish00.0%
Stryker Corporation · SYK · FY2025 Q1 · Calendar Q2 2025
Stryker Raises Organic Growth Outlook as Demand Holds Up
The current analysis supports a constructive operating trajectory: strong organic growth, demand for capital products, product launches, and international expansion were accompanied by a raised full-year organic-growth outlook. The case is tempered by tariff exposure, integration execution, pricing and margin questions, and the absence of reported-versus-consensus actuals in the supplied scorecard.
Reported After market closeNYSEHealthcare
$105.58B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $2.73
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $5.69B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+1.1%
Event window
SPY move
+1.5%
Same window
Abnormal move
-0.4%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+0.7%
Up to 20 sessions
SYKSPY benchmark
Ask FN2 about SYK FY2025 Q1
Transcript, numbers and history already loaded
What drove SYK's +1.1% move after FY2025 Q1 earnings?What changed in SYK's guidance and outlook in FY2025 Q1?Give me the bull and bear case for SYK after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management raised full-year organic sales growth guidance from 8%–9% to 8.5%–9.5% while reaffirming adjusted EPS guidance. The current analysis also reflects completed Inari integration, the U.S. spinal implant divestiture, and a more explicit focus on mitigating an estimated $200 million tariff impact.
Guidance delta
Management raised full-year organic sales growth guidance to 8.5%–9.5% and reaffirmed adjusted EPS guidance of $13.20–$13.45.
Key takeaways
- Q1 organic sales growth was 10.1%, with double-digit growth in MedSurg and Neurotechnology and high-single-digit growth in Orthopedics.
- Management cited record Mako installations, a healthy order book, and continued demand for capital products.
- The Inari acquisition was completed and described as integrating successfully; the U.S. spinal implant business was divested.
- Management identified pricing, cost discipline, and foreign-exchange benefits as offsets to an estimated $200 million tariff impact.
Management priorities
- Execute the Mako Spine launch in the second half of 2025 and the Mako Shoulder launch in the first quarter of 2026.
- Expand LIFEPAK 35 internationally, including Europe and Japan.
- Build adoption of Pangea and the Mako platform through international launches and continued product development.
- Continue tuck-in acquisitions and integrate Inari.
Follow SYK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$275.4Current
$260Low
$357.2Average
$465High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 8, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Stifel | Buy | Buy | Maintain | Sep 30, 2026 |
| TD Cowen | Hold | Hold | Maintain | Sep 22, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Sep 18, 2026 |
| Citigroup | Buy | Buy | Maintain | Sep 10, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Sep 9, 2026 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Aug 13, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Aug 3, 2026 |
| Truist Securities | Hold | Hold | Maintain | Jul 31, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 31, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 31, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 31, 2026 |
| BTIG | Buy | Buy | Maintain | Jul 31, 2026 |
| BMO Capital | Outperform | Market Perform | Upgrade | Jul 9, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Jun 5, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 4, 2026 |
| Needham | Buy | Buy | Maintain | May 1, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 9, 2026 |
| UBS | Neutral | Neutral | Maintain | Mar 17, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jan 9, 2026 |
| JMP Securities | Market Perform | Market Perform | Maintain | May 5, 2025 |
| Roth MKM | Buy | Buy | Maintain | May 2, 2025 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Dec 2, 2024 |
| Baird | Outperform | Outperform | Maintain | Oct 30, 2024 |
| B of A Securities | Buy | Neutral | Upgrade | Sep 5, 2023 |
| Argus Research | Buy | Buy | Maintain | May 25, 2023 |
| Jefferies | Buy | Buy | Maintain | May 2, 2023 |
| Deutsche Bank | Hold | Hold | Maintain | May 2, 2023 |
| Loop Capital | Buy | Buy | Maintain | Apr 17, 2023 |
| Edward Jones | Buy | Hold | Upgrade | Jul 28, 2022 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jul 22, 2022 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 28, 2022 |
| Oppenheimer | Perform | Perform | Maintain | Jul 28, 2021 |
| Northland Capital Markets | Outperform | Market Perform | Upgrade | Jul 28, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 28, 2021 |
| Raymond James | Outperform | Outperform | Maintain | Apr 28, 2021 |
| CFRA | Strong Buy | Strong Buy | Maintain | May 1, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 29, 2020 |
| Piper Jaffray | Overweight | Overweight | Maintain | Jul 26, 2019 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 26, 2019 |
| Argus | Buy | Buy | Maintain | May 5, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Jan 31, 2018 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Apr 27, 2016 |
| Sterne Agee | Buy | Neutral | Upgrade | Apr 27, 2016 |
| Brean Capital | Buy | Hold | Upgrade | Jan 27, 2016 |
| Northland Securities | Market Perform | Outperform | Downgrade | Jan 7, 2016 |
| SunTrust Robinson Humphrey | Neutral | Reduce | Upgrade | Apr 14, 2014 |
| Wunderlich Securities | Hold | Buy | Downgrade | Jul 19, 2013 |
| Wunderlich | Hold | Buy | Downgrade | Jul 19, 2013 |
| Standpoint Research | Hold | Buy | Downgrade | Dec 18, 2012 |
| Bank of America | Buy | Buy | Maintain | Dec 12, 2012 |
| PiperJaffray | Neutral | Overweight | Downgrade | Aug 2, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $275.4. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $375 | $278.5 | +36.2% | Oct 6, 2026 |
| Truist Financial | Analyst unavailable | $310 | $280.22 | +12.6% | Oct 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $330 | $278.86 | +19.8% | Sep 30, 2026 |
| Canaccord Genuity | Analyst unavailable | $385 | $280.14 | +39.8% | Sep 18, 2026 |
| BMO Capital | Joanne Wuensch | $317 | $277.89 | +15.1% | Sep 9, 2026 |
| Wells Fargo | Larry Biegelsen | $348 | $276.43 | +26.4% | Sep 9, 2026 |
| RBC Capital | Shagun Singh | $420 | $321.08 | +52.5% | Jul 31, 2026 |
| Raymond James | Analyst unavailable | $370 | $322.69 | +34.4% | Jul 31, 2026 |
| BTIG | Ryan Zimmerman | $358 | $322.13 | +30.0% | Jul 31, 2026 |
| Piper Sandler | Analyst unavailable | $390 | $348.37 | +41.6% | Jul 31, 2026 |
| Wolfe Research | Analyst unavailable | $375 | $348.37 | +36.2% | Jul 31, 2026 |
| BTIG | Analyst unavailable | $371 | $329.78 | +34.7% | Jul 13, 2026 |
| Argus Research | Analyst unavailable | $370 | $328.79 | +34.4% | Jul 9, 2026 |
| BMO Capital | Analyst unavailable | $369 | $326.85 | +34.0% | Jul 8, 2026 |
| Evercore ISI | Analyst unavailable | $350 | $319.22 | +27.1% | Jul 6, 2026 |
| Leerink Partners | Mike Kratky | $407 | $301.21 | +47.8% | Jun 5, 2026 |
| Truist Financial | Richard Newitter | $330 | $293.44 | +19.8% | May 4, 2026 |
| Barclays | Matt Miksic | $394 | $294.73 | +43.1% | May 4, 2026 |
| Goldman Sachs | David Roman | $361 | $294.73 | +31.1% | May 1, 2026 |
| Bernstein | Analyst unavailable | $410 | $302.38 | +48.9% | May 1, 2026 |
| Robert W. Baird | Analyst unavailable | $385 | $307.87 | +39.8% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $355 | $308.17 | +28.9% | May 1, 2026 |
| BTIG | Analyst unavailable | $379 | $315.18 | +37.6% | May 1, 2026 |
| Needham | Analyst unavailable | $418 | $315.18 | +51.8% | May 1, 2026 |
| Deutsche Bank | Analyst unavailable | $315 | $315.18 | +14.4% | May 1, 2026 |
| Jefferies | Matthew Taylor | $465 | $381.89 | +68.8% | Mar 4, 2026 |
| UBS | Analyst unavailable | $400 | $381.83 | +45.2% | Feb 24, 2026 |
| Barclays | Analyst unavailable | $469 | $369.56 | +70.3% | Feb 2, 2026 |
| Needham | Mike Matson | $454 | $365.62 | +64.9% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $437 | $369.02 | +58.7% | Jan 30, 2026 |
| BTIG | Ryan Zimmerman | $412 | $354.3 | +49.6% | Jan 30, 2026 |
| Bernstein | Lee Hambright | $465 | $367.21 | +68.8% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $399 | $367.21 | +44.9% | Jan 9, 2026 |
| Raymond James | Analyst unavailable | $418 | $348.79 | +51.8% | Jan 6, 2026 |
| Evercore ISI | Analyst unavailable | $390 | $347.68 | +41.6% | Jan 5, 2026 |
| Truist Financial | Richard Newitter | $400 | $366.38 | +45.2% | Nov 14, 2025 |
| RBC Capital | Shagun Singh | $435 | $365.14 | +58.0% | Nov 14, 2025 |
| Needham | Mike Matson | $448 | $373.42 | +62.7% | Nov 14, 2025 |
| Truist Financial | Analyst unavailable | $392 | $359.36 | +42.3% | Nov 3, 2025 |
| Evercore ISI | Analyst unavailable | $405 | $357.6 | +47.1% | Oct 31, 2025 |
| Truist Financial | Analyst unavailable | $407 | $370.88 | +47.8% | Oct 15, 2025 |
| UBS | Analyst unavailable | $408 | $364.6 | +48.1% | Oct 13, 2025 |
| Evercore ISI | Analyst unavailable | $410 | $366.28 | +48.9% | Oct 7, 2025 |
| Redburn Partners | Analyst unavailable | $420 | $376.8 | +52.5% | Sep 18, 2025 |
| Truist Financial | Analyst unavailable | $415 | $381.49 | +50.7% | Aug 4, 2025 |
| Bernstein | Lee Hambright | $450 | $381.36 | +63.4% | May 5, 2025 |
| BTIG | Ryan Zimmerman | $403 | $353.42 | +46.3% | Apr 14, 2025 |
| Goldman Sachs | Analyst unavailable | $422 | $389.92 | +53.2% | Mar 4, 2025 |
| Argus Research | David Toung | $450 | $391.14 | +63.4% | Feb 3, 2025 |
| Truist Financial | Richard Newitter | $409 | $359.17 | +48.5% | Dec 18, 2024 |
| Morgan Stanley | Patrick Wood | $445 | $390.9 | +61.6% | Dec 2, 2024 |
| Citigroup | Joanne Wuensch | $411 | $363.43 | +49.2% | Oct 31, 2024 |
| Piper Sandler | Matt O'Brien | $420 | $367.95 | +52.5% | Oct 30, 2024 |
| Truist Financial | Richard Newitter | $380 | $365.42 | +38.0% | Oct 30, 2024 |
| Canaccord Genuity | Kyle Rose | $400 | $359.01 | +45.2% | Oct 30, 2024 |
| BTIG | Ryan Zimmerman | $394 | $359.01 | +43.1% | Oct 30, 2024 |
| Truist Financial | Richard Newitter | $370 | $356.45 | +34.4% | Oct 14, 2024 |
| Piper Sandler | Matt O\'Brien | $380 | $365.22 | +38.0% | Sep 10, 2024 |
| BTIG | Ryan Zimmerman | $374 | $358.51 | +35.8% | Aug 28, 2024 |
| Truist Financial | Richard Newitter | $345 | $327 | +25.3% | Aug 1, 2024 |
| BTIG | Ryan Zimmerman | $360 | $330.22 | +30.7% | Jul 31, 2024 |
| Goldman Sachs | David Roman | $372 | $341.14 | +35.1% | May 30, 2024 |
| Argus Research | David Toung | $380 | $330.51 | +38.0% | May 22, 2024 |
| Needham | Mike Matson | $392 | $330.51 | +42.3% | May 22, 2024 |
| BTIG | Ryan Zimmerman | $366 | $342.05 | +32.9% | Apr 15, 2024 |
| Piper Sandler | Matt O'Brien | $280 | $253.81 | +1.7% | Jan 31, 2023 |
| Morgan Stanley | Analyst unavailable | $260 | $254.93 | -5.6% | Jan 6, 2023 |
| BTIG | Ryan Zimmerman | $268 | $239.65 | -2.7% | Dec 21, 2022 |
| Cowen & Co. | Cowen Cowen | $283 | $239.84 | +2.8% | Dec 19, 2022 |
| Barclays | Analyst unavailable | $257 | $238.76 | -6.7% | Dec 2, 2022 |
| Piper Sandler | Matt O’Brien | $260 | $206.93 | -5.6% | Sep 24, 2022 |
| BTIG | Analyst unavailable | $238 | $202.61 | -13.6% | Sep 6, 2022 |
| BTIG | Analyst unavailable | $244 | $192.91 | -11.4% | Jul 18, 2022 |
| Stifel Nicolaus | Analyst unavailable | $245 | $193.26 | -11.0% | Jul 18, 2022 |
| Argus Research | David Toung | $270 | $232.41 | -2.0% | May 23, 2022 |
| Truist Financial | Richard Newitter | $280 | $236.97 | +1.7% | May 3, 2022 |
| Morgan Stanley | Analyst unavailable | $270 | $236.97 | -2.0% | May 2, 2022 |
| Piper Sandler | Matt O’Brien | $290 | $241.26 | +5.3% | Apr 30, 2022 |
| Wells Fargo | Analyst unavailable | $286 | $246.64 | +3.8% | Apr 29, 2022 |
| BTIG | Ryan Zimmerman | $278 | $276.37 | +0.9% | Apr 21, 2022 |
| RBC Capital | Shagun Singh | $272 | $261.7 | -1.2% | Apr 16, 2022 |
| Bernstein | Lee Hambright | $295 | $267.34 | +7.1% | Mar 19, 2022 |
| Bank of America Securities | Travis Steed | $300 | $266.47 | +8.9% | Mar 3, 2022 |
| J.P. Morgan | Robbie Marcus | $265 | $247.76 | -3.8% | Jan 28, 2022 |
| UBS | Matthew Taylor | $267 | $247.76 | -3.1% | Jan 28, 2022 |
| BTIG | Ryan Zimmerman | $273 | $247.76 | -0.9% | Jan 28, 2022 |
| Leerink Partners | Danielle Antalffy | $285 | $247.76 | +3.5% | Jan 28, 2022 |
| Piper Sandler | Matthew O'Brien | $315 | $244.7 | +14.4% | Jan 27, 2022 |
| Deutsche Bank | Pito Chickering | $285 | $254.03 | +3.5% | Jan 21, 2022 |
| Motley Fool | Rick Aristotle Munarriz | $278 | $259.21 | +0.9% | Dec 9, 2021 |
| Loop Capital Markets | Jason Wittes | $305 | $253.11 | +10.7% | Dec 6, 2021 |
| Argus Research | David Toung | $320 | $267.18 | +16.2% | Jul 29, 2021 |
| Canaccord Genuity | Kyle Rose | $290 | $266.68 | +5.3% | Jul 28, 2021 |
| Cowen & Co. | Josh Jennings | $305 | $266.68 | +10.7% | Jul 28, 2021 |
| Credit Suisse | Matt Miksic | $311 | $266.68 | +12.9% | Jul 28, 2021 |
| Oppenheimer | Steven Lichtman | $288 | $266.68 | +4.6% | Jul 28, 2021 |
Track every rating change on SYK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationStryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items.…
Historical context
All SYK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the SYK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-17T00:02:52.217204+00:00
- Polygon adjusted daily market bars · 2026-10-08T02:50:43.990059+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-08T02:50:43.987346+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-08. For educational purposes only; not investment advice.